L'hypertension artérielle aux JESFC 2014.

À l'occasion des 24èmes Journées Européennes de la Société Française de Cardiologie du 15 au 18 janvier 2014, le Pr Pathak revient sur les trois informations principales discutées en conférence...

Resistant Hypertension Course Scientific Board’s view on Medtronic’s press release about SYMPLICITY HTN-3

In light of Medtronic’s announcement of Thursday, 9th January 2014, about SYMPLICITY HTN-3, the Resistant Hypertension Course Scientific Board shares its point of view.

Medtronic, Inc. announced yesterday that its U.S. trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, has met its primary safety endpoint, while it did not reach its primary efficacy endpoint, defined as a difference of, at least, 15 mmHg office systolic blood pressure, between sham and active renal denervation groups.

The RHC Board shares its point of view:

Pages